Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.
about
Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseasesMicroglia-Mediated Neuroinflammation and Neurotrophic Factor-Induced Protection in the MPTP Mouse Model of Parkinson's Disease-Lessons from Transgenic MiceGDNF-transfected macrophages produce potent neuroprotective effects in Parkinson's disease mouse modelNigrostriatal dynein changes in A53T alpha-synuclein transgenic mice.Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophagesCell-mediated drug delivery.Identifying early inflammatory changes in monocyte-derived macrophages from a population with IQ-discrepant episodic memory.Monocytes-derived macrophages mediated stable expression of human brain-derived neurotrophic factor, a novel therapeutic strategy for neuroAIDS.Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson's diseaseEicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor.Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's diseaseInflammatory cells and cytokines in the olfactory bulb of a rat model of neuroinflammation; insights into neurodegeneration?Delayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.An update on gene therapy in Parkinson's disease.Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.Heterogeneity of CNS myeloid cells and their roles in neurodegeneration.Genetic approaches to study glial cells in the rodent brain.The immunological challenges of cell transplantation for the treatment of Parkinson's disease.The role of glia in α-synucleinopathies.Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms.Neuropharmacologic Approaches to Restore the Brain's Microenvironment.Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells.Differentiation of human and murine induced pluripotent stem cells to microglia-like cells.Extracellular Vesicles in Brain Tumors and Neurodegenerative Diseases.A DNA methyltransferase inhibitor, 5-aza-2'-deoxycytidine, exacerbates neurotoxicity and upregulates Parkinson's disease-related genes in dopaminergic neurons.Macrophage LXRα gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-/-) mice.Differential contribution of microglia and monocytes in neurodegenerative diseases.GDNF-expressing macrophages mitigate loss of dopamine neurons and improve Parkinsonian symptoms in MitoPark mice.Effect of GDNF on Morphology, Proliferation, and Phagocytic Activity of Rat Neonatal Cortex Isolated MicrogliaOutside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease
P2860
Q21133553-A30CE824-13A5-4053-A186-3452AAC850F4Q26773064-37EFD353-9C8E-44EC-A37D-3C573333B95FQ28543023-5F0C42DF-021C-453B-8A0F-1E33FAC26D72Q34140861-3DD1C5E2-05C8-4463-A876-B59987585736Q34476803-FA040495-7684-4D90-BE08-78B24D483BEAQ34632979-16413915-C813-4C35-8057-1D0859677FE3Q34709440-02CEFBD7-B85E-44EB-940A-CABFE55CB87DQ34721095-F1289E4A-0765-4706-815A-8DDC9B6B7F62Q35088011-FB36C05F-0070-4291-98CD-92D88CA50178Q35194750-A0EBB130-0FAE-4F20-AD5E-C656F813EA94Q35632000-A87A2179-3123-418D-B09C-3FD23AD398DCQ36048615-DE9C4DDC-8AB0-46A3-944F-83CD0CE9C63DQ36055556-599DC693-D354-4094-8DFE-B694D9C8FE26Q36819317-AEF303A8-B125-4729-B7BE-41606413504AQ37003565-8D70D9E5-793C-469E-BF43-368B7EDF9D45Q37710820-5CC63299-0465-4809-ADED-2865F151BD14Q37863587-56432CAE-2EF1-4FD6-B501-B95BD9B4EA21Q37874476-5343D940-8871-4420-B72C-715792ACCFC6Q37939514-B95B1A62-96C5-4127-9D19-4BDB5EFE3953Q37967602-658EADC8-52E3-4668-B41A-A922E6523233Q38004257-CD361151-9644-4842-98E0-D6D42DB524CFQ38039880-E7BD0DD8-1BF9-4227-8360-EDAE8F3A4D99Q38112214-A75DA01C-8551-4D86-8977-ADDCD9591C72Q38879533-0AE29667-F6E2-4F53-A02D-10D54B3B46E2Q38966488-E0DCDC7E-8331-401E-819C-D3A24C4F8139Q40311122-B9E60AD5-743D-4AF1-87B0-57B5321E3EC1Q41605967-D63C0725-BC88-4954-973B-08F9AEBE4B13Q42712712-8D7EF783-90CA-4CF5-99C0-77D222B172E9Q45868148-24CDE0B3-E8C8-42EC-808B-61EB619BBCD1Q48141250-6CC2DCC7-CCB4-412E-A26A-1783DFA33353Q52721898-D0E4B847-EC95-4F01-ACBB-C6D2258FE925Q58051763-D3970CA6-F5FE-4D16-98C5-9C8ADE5DD8BBQ59136331-4C063669-0252-40AF-88FC-B8AC7FC08792
P2860
Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.
@ast
Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.
@en
type
label
Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.
@ast
Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.
@en
prefLabel
Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.
@ast
Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.
@en
P2093
P2860
P921
P356
P1433
P1476
Macrophage-mediated GDNF deliv ...... ategy for Parkinson's disease.
@en
P2093
Guiming Li
James L Roberts
Robert A Clark
Syed Z Imam
William W Morgan
P2860
P304
P356
10.1038/MT.2010.107
P577
2010-06-08T00:00:00Z